Table 1.
Patient characteristics in the training cohort, validation cohort, and SEP cohort.
| Training cohort no SEP, n = 287 | Validation cohort no SEP, n = 202 | SEP cohort, n = 401 | |
|---|---|---|---|
| Median age at alloSCT (years, range) | 50 (17–71) | 50 (19–72) | 57 (19–76) |
| Sex (n, %) | |||
| Female | 114 (40) | 72 (36) | 161 (40) |
| Male | 173 (60) | 130 (64) | 240 (60) |
| Donor | |||
| RD | 108 (38) | 65 (32) | 104 (26) |
| UD | 179 (62) | 137 (68) | 297 (74) |
| Donor–recipient HLA matching | |||
| Matched donor | 214 (75) | 195 (97) | 327 (82) |
| Mismatched dono | 73 (25) | 7 (3) | 74 (18) |
| Sex mismatch (donor–recipient) (n, %) | |||
| Male–male, Female–Female | 164 (57) | 109 (54) | 222 (55) |
| Male–female | 71 (24) | 45 (22) | 103 (26) |
| Female–male | 52 (19) | 48 (24) | 76 (19) |
| Disease (n, %) | |||
| AML | 76 (26) | 83 (41) | 146 (36) |
| MDS, MPN, AA | 45 (16) | 44 (22) | 72 (18) |
| Lymphoma, ALL, CLL | 111 (39) | 61 (30) | 141 (35) |
| MM, Amyloidosis | 55 (19) | 14 (7) | 42 (11) |
| Disease score before alloSCT (n, %) | |||
| 0 | 99 (34) | 92 (46) | 138 (34) |
| 1 | 41 (15) | 80 (40) | 147 (37) |
| 2 | 134 (47) | 25 (12) | 108 (27) |
| NA | 13 (5) | 5 (2) | 8 (2) |
| Stem cell source (n, %) | |||
| Peripheral stem cells | 272 (95) | 200 (99) | 382 (95) |
| Bone marrow stem cells | 15 (8) | 2 (1) | 19 (5) |
| Conditioning (n, %) | |||
| MAC | 51 (18) | 82 (41) | 15 (4) |
| APL | 7 (2) | 46 (11) | |
| RIC | 229 (80) | 120 (59) | 340 (85) |
| ATG (n, %) | |||
| No | 140 (49) | 81 (40) | 103 (26) |
| Yes | 147 (51) | 121 (60) | 298 (74) |
| Combined genetic score (n, %) | |||
| Low-risk | 190 (66) | 160 (79) | 235 (59) |
| High risk | 52 (18) | 42 (21) | 68 (17) |
| NA (no DNA) | 45 (16) | 98 (24) | |
| CXCL9 prea median (pg/mL, IQR) |
n = 109 204.5 (108.7–629.5) |
n = 296 175.7 (72.3–542.1) |
|
| CXCL9 day 28+b median (pg/mL, IQR) |
n = 152 315.3 (141.2–673.3) |
n = 342 295.5 (114.8–598.8) |
|
| CXCL10 pre median (pg/mL, IQR) | |||
| CXCL10 day 28+ median (pg/mL, IQR) |
n = 146 152.9 (65.6–283.7) |
n = 333 128.7 (56.7–242.0) |
|
| CXCL11 pre median (pg/mL, IQR) |
n = 103 79.8 (24.3–183.4) |
n = 289 70.4 (24.5–165.0) |
|
| CXCL11 day 28+ median (pg/mL, IQR) |
n = 146 119.2 (61.2–211.8) |
n = 333 122.1 (53.5–204.6) |
|
SEP statin-based endothelial prophylaxis, AA aplastic anemia, ALL acute lymphoblastic leukemia, alloSCT allogeneic stem cell transplantation, AML acute myelogenous leukemia, ATG antithymocyte globulin, CLL chronic lymphocytic leukemia, disease score: 0 = CR1, 1 = CR2, 2 = all other, MAC myeloablative conditioning, MPS myeloproliferative syndrome, MM multiple myeloma, RD related donor, RIC reduced intensity conditioning, UD unrelated donor.
aMeasured pre-transplant.
bMeasured at day 28 post transplant.